Fig. 9From: PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients’ RBCs ex vivo in the frame of Protein Replacement TherapyMethylene violet staining for the evaluation of HbH-IBs’ reduction, in HbH RBCs upon incubation with 10xHisXaSITE-TAT-α-globin-HA. Patient 2: A Untreated HbH patient’s RBCs, and B HbH patient’s RBCs incubated with IBs, enriched in 10xHis-XaSITE-TAT-α-globin-HA, for 48 h. Patient 3: A Untreated HbH patient’s RBCs, B HbH patient’s RBCs incubated with 1 M l-Arg, for 48 h, C HbH patient’s RBCs incubated with IBs, enriched in 10xHis-XaSITE-TAT-α-globin-HA, for 48 hBack to article page